Autopsy report · NCT04493099
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
Cause of deathFunding or business
“The original sponsor was acquired by a new company and has elected to end funding for all Investigator Sponsored Trials (ISTs)”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1, Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
- Interventions
- Alvocidib Hydrochloride; Decitabine; Venetoclax
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
“sponsor and investigator 's decision” - Unipolar Microplasma Radiofrequency Device: In-vivo Histologic Study
“Per Investigator and sponsor decision” - DELP for Acute Hemorrhagic Stroke
“the research sponsors stopped further funding due to a planning of a multi-center trial” - Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
“Sponsor no longer pursuing regulatory approval of investigational device” - Adaptation of the PCIP for Children Aged 6 to 11
“We secured funding to run a cluster randomized trial and approval from the sponsor to transfer the money for this project to the new larger trial.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.